ATE269354T1 - Depsipeptide und deren analoge zur verwendung als immunosuppressiva - Google Patents

Depsipeptide und deren analoge zur verwendung als immunosuppressiva

Info

Publication number
ATE269354T1
ATE269354T1 AT00983997T AT00983997T ATE269354T1 AT E269354 T1 ATE269354 T1 AT E269354T1 AT 00983997 T AT00983997 T AT 00983997T AT 00983997 T AT00983997 T AT 00983997T AT E269354 T1 ATE269354 T1 AT E269354T1
Authority
AT
Austria
Prior art keywords
depsipeptides
immunosuppressants
grant
analogues
suffering
Prior art date
Application number
AT00983997T
Other languages
English (en)
Inventor
Soren Skov
Original Assignee
Xcyte Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26865325&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE269354(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Xcyte Therapies Inc filed Critical Xcyte Therapies Inc
Application granted granted Critical
Publication of ATE269354T1 publication Critical patent/ATE269354T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K11/02—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins ; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT00983997T 1999-12-08 2000-12-06 Depsipeptide und deren analoge zur verwendung als immunosuppressiva ATE269354T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16973199P 1999-12-08 1999-12-08
US19358200P 2000-03-30 2000-03-30
PCT/US2000/033169 WO2001042282A1 (en) 1999-12-08 2000-12-06 Depsipeptide and congeners thereof for use as immunosuppressants

Publications (1)

Publication Number Publication Date
ATE269354T1 true ATE269354T1 (de) 2004-07-15

Family

ID=26865325

Family Applications (3)

Application Number Title Priority Date Filing Date
AT00983997T ATE269354T1 (de) 1999-12-08 2000-12-06 Depsipeptide und deren analoge zur verwendung als immunosuppressiva
AT04007814T ATE353663T1 (de) 1999-12-08 2000-12-06 Verwendung von depsipeptide und deren analoge als immunosuppressiva zur behandlung von infektionskrankheiten, autoimmunerkrankungen, allergien und hyperproliferativer hautkrankheiten
AT07002930T ATE470447T1 (de) 1999-12-08 2000-12-06 Depsipetid und kongenere davon für den einsatz als immunsuppressiva zur vorbeugung und behandlung von abstossreaktionen infolge einer transplantation und zur induktion des apoptosis in aktivierten cd4 oder cd8 t-zellen

Family Applications After (2)

Application Number Title Priority Date Filing Date
AT04007814T ATE353663T1 (de) 1999-12-08 2000-12-06 Verwendung von depsipeptide und deren analoge als immunosuppressiva zur behandlung von infektionskrankheiten, autoimmunerkrankungen, allergien und hyperproliferativer hautkrankheiten
AT07002930T ATE470447T1 (de) 1999-12-08 2000-12-06 Depsipetid und kongenere davon für den einsatz als immunsuppressiva zur vorbeugung und behandlung von abstossreaktionen infolge einer transplantation und zur induktion des apoptosis in aktivierten cd4 oder cd8 t-zellen

Country Status (16)

Country Link
US (2) US6403555B1 (de)
EP (3) EP1246839B1 (de)
JP (4) JP4824890B2 (de)
KR (1) KR20020062956A (de)
CN (1) CN1414971A (de)
AT (3) ATE269354T1 (de)
AU (1) AU762525B2 (de)
BR (1) BR0016154A (de)
CA (1) CA2393682C (de)
DE (3) DE60011678T2 (de)
DK (1) DK1438966T3 (de)
ES (3) ES2225282T3 (de)
HK (2) HK1049849B (de)
IL (2) IL149995A0 (de)
PT (1) PT1438966E (de)
WO (1) WO2001042282A1 (de)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6822267B1 (en) * 1997-08-20 2004-11-23 Advantest Corporation Signal transmission circuit, CMOS semiconductor device, and circuit board
US8119159B2 (en) 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
AU2001280109A1 (en) * 2000-09-01 2002-03-22 Fujisawa Pharmaceutical Co. Ltd. A method of producing fr901228
AU2002243231A1 (en) * 2000-11-21 2002-07-24 Wake Forest University Method of treating autoimmune diseases
US6632553B2 (en) * 2001-03-27 2003-10-14 Mti Microfuel Cells, Inc. Methods and apparatuses for managing effluent products in a fuel cell system
US8470783B2 (en) 2001-08-21 2013-06-25 Astellas Pharma Inc. Medicinal use of histone deacetylase inhibitor and method of evaluating antitumor effect thereof
US8946295B2 (en) * 2002-07-25 2015-02-03 Sunny Pharmtech Inc. Histone hyperacetylating agents for promoting wound healing and preventing scar formation
US20060275370A1 (en) * 2002-07-25 2006-12-07 Yih-Lin Chung Method and compositions for treatment of epithelial damage
US8163764B2 (en) * 2002-04-26 2012-04-24 Asan Laboratories Company (Cayman) Limited Skincare methods
US6809118B2 (en) * 2002-07-25 2004-10-26 Yih-Lin Chung Methods for therapy of radiation cutaneous syndrome
US8883148B2 (en) * 2002-04-26 2014-11-11 Asan Laboratories Company (Cayman), Limited Prevention of joint destruction
US8846039B2 (en) * 2002-04-26 2014-09-30 Asan Laboratories Company (Cayman), Limited Method for ameliorating pruritus
EP1547617B1 (de) * 2002-08-20 2010-04-28 Astellas Pharma Inc. Hemmer des abbaus der extrazellulären matrix von arthrodia-knorpel
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7250514B1 (en) 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
EP1608628A2 (de) 2003-03-17 2005-12-28 Takeda San Diego, Inc. Inhibitoren der histondeacetylase
ATE468113T1 (de) * 2003-06-27 2010-06-15 Astellas Pharma Inc Therapeutisches mittel für ein weichteilsarkom
WO2005007109A2 (en) * 2003-07-09 2005-01-27 Henry Ford Health System Methods and compositions for cancer therapy using a novel adenovirus
DE602004027824D1 (de) * 2003-09-25 2010-08-05 Astellas Pharma Inc Antitumorales mittel mit einem histon-deacetylase-hemmer und einem topoisomerase-ii-hemmer
US20050159470A1 (en) * 2003-12-19 2005-07-21 Syrrx, Inc. Histone deacetylase inhibitors
WO2005066151A2 (en) * 2003-12-19 2005-07-21 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7951780B2 (en) * 2004-02-25 2011-05-31 Astellas Pharma Inc. Antitumor agent
US20050187148A1 (en) * 2004-02-25 2005-08-25 Yoshinori Naoe Antitumor agent
EP1812036A2 (de) * 2004-11-17 2007-08-01 The University Of Chicago Histon-deacetylase-hemmer und anwendungsverfahren
US7642275B2 (en) 2004-12-16 2010-01-05 Takeda San Diego, Inc. Histone deacetylase inhibitors
EP1896436A2 (de) 2005-05-11 2008-03-12 Takeda San Diego, Inc. Inhibitoren der histondeacetylase
GB0511266D0 (en) * 2005-06-02 2005-07-13 Trust Chemical compounds
AU2006270322A1 (en) * 2005-07-14 2007-01-25 Takeda San Diego, Inc. Histone deacetylase inhibitors
EP1937236A2 (de) * 2005-09-07 2008-07-02 Braincells, Inc. Modulation der neurogenese durch hdac-hemmung
JP2009519224A (ja) * 2005-11-18 2009-05-14 グロスター ファーマシューティカルズ， インコーポレイテッド Ｈｄａｃインヒビターｆｋ２２８の代謝産物誘導体
JP2009525955A (ja) * 2006-01-13 2009-07-16 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
EP2007397B1 (de) 2006-04-07 2013-07-24 Merrion Research III Limited Feste orale Darreichungsform mit einem Verstärker
EP2049139A4 (de) * 2006-04-24 2009-06-24 Gloucester Pharmaceuticals Inc Behandlung ras-exprimierender tumore
US8957027B2 (en) 2006-06-08 2015-02-17 Celgene Corporation Deacetylase inhibitor therapy
EP2040731A4 (de) * 2006-06-09 2010-05-19 Merrion Res Iii Ltd Feste orale dosierform mit einem verstärkungsmittel
US7883855B2 (en) 2006-07-21 2011-02-08 Abbott Laboratories Immunosuppressant drug extraction reagent for immunoassays
WO2008036682A2 (en) 2006-09-18 2008-03-27 Raptor Pharmaceutical Inc. Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates
AU2007323215B2 (en) * 2006-11-22 2012-07-19 Karus Therapeutics Limited Depsipeptides and their therapeutic use
GB0623388D0 (en) * 2006-11-23 2007-01-03 Univ Southampton Chemical compounds
CA2674309A1 (en) * 2006-12-29 2008-07-10 Gloucester Pharmaceuticals, Inc. Preparation of romidepsin
US7914999B2 (en) 2006-12-29 2011-03-29 Abbott Laboratories Non-denaturing lysis reagent
CN101687010A (zh) 2006-12-29 2010-03-31 格洛斯特制药公司 制备Romidepsin
WO2008151306A1 (en) * 2007-06-05 2008-12-11 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University Synthesis of cyclodepsipeptide compounds having antineoplastic and/or antimicrobial activity
GB0715750D0 (en) * 2007-08-13 2007-09-19 Karus Therapeutics Ltd Chemical compounds
CA2709272C (en) * 2007-12-19 2015-03-10 Abbott Laboratories Immunosuppressant drug extraction reagent for immunoassays
US8999383B2 (en) 2008-05-07 2015-04-07 Merrion Research Iii Limited Compositions of GnRH related compounds and processes of preparation
DK2293846T3 (da) * 2008-05-22 2013-10-14 Karus Therapeutics Ltd Depsipeptider og deres terapeutiske anvendelse
WO2009141657A1 (en) * 2008-05-22 2009-11-26 Karus Therapeutics Limited Depsipeptides and their therapeutic use
WO2010148572A1 (en) * 2009-06-26 2010-12-29 Asan Laboratories Co., Ltd. Method for treating or ameliorating mucocutaneous or ocular toxicities
TWI412359B (zh) * 2009-07-07 2013-10-21 Asan Lab Co Ltd 組織蛋白去乙醯酵素抑制劑在製備治療或減緩黏膜／皮膚或眼睛毒性或副作用之藥物的用途
US9089484B2 (en) 2010-03-26 2015-07-28 Merrion Research Iii Limited Pharmaceutical compositions of selective factor Xa inhibitors for oral administration
NZ706052A (en) 2010-07-12 2016-07-29 Celgene Corp Romidepsin solid forms and uses thereof
US8859502B2 (en) 2010-09-13 2014-10-14 Celgene Corporation Therapy for MLL-rearranged leukemia
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
KR20140026354A (ko) 2011-01-07 2014-03-05 메리온 리서치 Ⅲ 리미티드 경구 투여용 철의 제약 조성물
EP2762148B1 (de) * 2011-09-30 2017-12-27 Tohoku University Depsipeptid als phosphatidylinositol-3-kinaseinhibitor und verwendung davon zur behandlung von krebs
WO2013148260A1 (en) 2012-03-30 2013-10-03 Washington University Methods for modulating tau expression for reducing seizure and modifying a neurodegenerative syndrome
AU2013202506B2 (en) 2012-09-07 2015-06-18 Celgene Corporation Resistance biomarkers for hdac inhibitors
AU2013202507B9 (en) 2012-11-14 2015-08-13 Celgene Corporation Inhibition of drug resistant cancer cells
TW202246503A (zh) 2013-07-19 2022-12-01 美商百健Ｍａ公司 用於調節τ蛋白表現之組合物
NZ630311A (en) 2013-12-27 2016-03-31 Celgene Corp Romidepsin formulations and uses thereof
KR20150140177A (ko) * 2014-06-05 2015-12-15 한미약품 주식회사 단백질 및 펩타이드의 면역원성을 감소시키는 방법
JP7211704B2 (ja) 2015-01-29 2023-01-24 ノヴォ ノルディスク アー／エス Ｇｌｐ－１アゴニスト及び腸溶コーティングを含む錠剤
CN110760564A (zh) * 2019-10-16 2020-02-07 菲诺克生物科技(上海)有限公司 细胞周期检测方法及其所用试剂与试剂盒

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4268516A (en) 1978-10-11 1981-05-19 Pfizer Inc. [1]Benzothiopyrano[4,3-c]pyrazoles as immunoregulatory agents
US4950649A (en) * 1980-09-12 1990-08-21 University Of Illinois Didemnins and nordidemnins
GB8817743D0 (en) * 1988-07-26 1988-09-01 Fujisawa Pharmaceutical Co Fr901228 substance & preparation thereof
AU3972193A (en) 1992-04-07 1993-11-08 Scripps Research Institute, The Method for inducing tolerance to an antigen using butyrate
KR100398819B1 (ko) 1993-09-02 2004-02-05 트러스티스 오브 다트마우스 칼리지 gp39길항제를포함하는약제조성물
US5591717A (en) 1994-04-06 1997-01-07 Rojko; Jennifer L. Branched apogenic peptide for inducing apoptosis
CA2191586A1 (en) 1994-06-03 1995-12-14 Carl H. June Methods for selectively stimulating proliferation of t cells
WO1999014241A2 (en) 1997-09-17 1999-03-25 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US5843943A (en) 1994-12-29 1998-12-01 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction
US5962019A (en) 1995-08-25 1999-10-05 Sangstat Medical Corporation Oral cyclosporin formulations
US5891653A (en) 1995-12-29 1999-04-06 Attfield; Derrick Cecil Method of suppressing graft rejection by means of stress proteins
US6777217B1 (en) * 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
WO1998039412A1 (en) 1997-03-03 1998-09-11 Duke University Immunosuppression
DE19713626A1 (de) * 1997-04-02 1998-10-08 Bayer Ag Neue Thiodepsipeptide zur Bekämpfung von Endoparasiten und ein einfaches Verfahren zu ihrer Herstellung
WO1998046640A2 (en) 1997-04-15 1998-10-22 Coulter International Corp. Methods and compositions for inducing immunosuppression
WO1999011659A1 (fr) 1997-09-02 1999-03-11 Japan Energy Corporation Derives tetrapeptides cycliques et leur utilisation medicinale
WO1999015174A1 (en) 1997-09-22 1999-04-01 Sloan-Kettering Institute For Cancer Research Reverse prenyl compounds as immunosuppressants
AU1399199A (en) 1997-11-14 1999-06-07 Merck & Co., Inc. Immunosuppressant tetracyclic triterpenes
WO1999030730A1 (en) 1997-12-15 1999-06-24 Universite Laval Methods and compositions for improving the success of cell transplantation in a host
JPH11180873A (ja) 1997-12-22 1999-07-06 Kaken Shoyaku Kk ＮＦ−κＢ活性阻害剤
US6001815A (en) * 1997-12-25 1999-12-14 Nisshin Flour Milling Co., Ltd. Depsipeptides containing N-substituted glycine residue
US6211145B1 (en) * 1997-12-25 2001-04-03 Nisshin Flour Milling Co., Ltd. Bicyclic depsipeptides
US6252041B1 (en) * 1998-01-27 2001-06-26 Nisshin Flour Milling Co., Ltd. Depsipeptides containing non-natural amino acids
US6287843B1 (en) 1998-04-03 2001-09-11 Pioneer Hi-Bred International, Inc. Maize histone deacetylases and their use
ES2265906T3 (es) * 1999-01-13 2007-03-01 Astellas Pharma Inc. Nuevo compuesto depsipeptidico.

Also Published As

Publication number Publication date
ATE470447T1 (de) 2010-06-15
EP1779859A3 (de) 2007-05-16
DE60033453D1 (de) 2007-03-29
CN1414971A (zh) 2003-04-30
AU762525B2 (en) 2003-06-26
WO2001042282A1 (en) 2001-06-14
DE60044542D1 (de) 2010-07-22
EP1438966A2 (de) 2004-07-21
CA2393682C (en) 2012-01-31
EP1438966B1 (de) 2007-02-14
AU2068001A (en) 2001-06-18
EP1246839A1 (de) 2002-10-09
US6403555B1 (en) 2002-06-11
US6548479B1 (en) 2003-04-15
IL149995A (en) 2009-09-01
HK1049849B (zh) 2004-12-03
ES2347284T3 (es) 2010-10-27
EP1438966A3 (de) 2004-08-04
ATE353663T1 (de) 2007-03-15
US20020045575A1 (en) 2002-04-18
ES2225282T3 (es) 2005-03-16
DE60033453T2 (de) 2007-11-29
BR0016154A (pt) 2003-02-25
KR20020062956A (ko) 2002-07-31
DE60011678D1 (de) 2004-07-22
EP1779859A2 (de) 2007-05-02
EP1779859B1 (de) 2010-06-09
DK1438966T3 (da) 2007-06-11
JP2003516418A (ja) 2003-05-13
JP2014205714A (ja) 2014-10-30
HK1049849A1 (en) 2003-05-30
WO2001042282A9 (en) 2002-05-30
JP2013107902A (ja) 2013-06-06
DE60011678T2 (de) 2005-07-14
IL149995A0 (en) 2002-12-01
EP1246839B1 (de) 2004-06-16
ES2282751T3 (es) 2007-10-16
JP2011084585A (ja) 2011-04-28
HK1070268A1 (en) 2005-06-17
JP4824890B2 (ja) 2011-11-30
PT1438966E (pt) 2007-05-31
CA2393682A1 (en) 2001-06-14

Similar Documents

Publication Publication Date Title
ATE269354T1 (de) Depsipeptide und deren analoge zur verwendung als immunosuppressiva
CY1116107T1 (el) Ενωσεις για χρηση στην αγωγη αυτοανοσων παθησεων, ανοσο-αλλεργικων παθησεων και απορριψης μεταμοσχευσης οργανων ή ιστων
EP2418220A3 (de) Interferon-Alpha-Antikörper und deren Verwendungen
UA86344C2 (ru) Способ лечения сосудистых заболеваний
DE60043120D1 (de) Polyhydroxystilbene und -stilbenoxide als antipsoriasismittel und proteinkinasehemmer
EP1688425A3 (de) Cyclische Salen-Metall-Verbindungen als Einfänger von Sauerstoffradikalen und verwendbar als Antioxidantien bei der Behandlung und Vorbeugung von Krankheiten
WO2004069201A3 (en) Compounds useful in coating stents to prevent and treat stenosis and restenosis
HUP0002755A2 (hu) Eljárások szklerózis multiplexben szenvedő betegek kezelésére konszenzus interferonnal
BG104091A (en) Cd154 blockade therapty in tissue transplantation of pancreatic isles
DE60231131D1 (de) Vakzine und verwendung davon zur behandlung amyotrophischer lateralsklerose
DE602005016729D1 (de) Verwendung von 5'-methylthioadenosin zur prävention und/oder behandlung von autoimmunkrankheiten und/oder transplantatabstossung
IL99778A0 (en) Compositions for the treatment of cell proliferation disorders
PL324424A1 (en) Therapeutic factors and autoimmunological diseases
DE60229240D1 (de) Verwendung eines analoges des vitamins d3 zur behandlung des autoimmunen diabetes
ATE546154T1 (de) Anti-angiogenetisches mittel und seine verwendung bei der krebsbehandlung
IT1285754B1 (it) Apparecchiatura per il trattamento estetico di parti del corpo umano
NO20022109D0 (no) Anvendelse av treosulfan for behandling av pasienter för benmargs- eller blodstamcelletansplantasjon
DE69731284D1 (de) Verwendung Von Coxiella Bakterien zur Behandlung von Autoimmunkrankheiten
AU7477101A (en) Human site-1 protease promoter
DE69932815D1 (de) Cyclophilin als Allergen identifiziert
TW200519078A (en) 2-alkylidene-19-nor-vitamin d derivatives for the treatment of a second hip fracture
LT2002105A (en) Novel use of siberian fir oil

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties